LEXEO Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

NEW YORK – January 5, 2022 (GLOBE NEWSWIRE) – LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic conditions, today announced that R. Nolan Townsend, Chief Executive Officer of LEXEO Therapeutics, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 5:30 PM E.T.



Lexeo JPM Press Release - 1.05.22
.pdf
Download PDF • 97KB



178 views